Drug intelligence / Profile preview

MSI1-C-terminus decoy peptide

Development stage
Preclinical
Lead developer
Taipei Veterans General Hospital
Modality
Peptides
Administration
Intratumoral
01

Overview

MSI1-C-terminus decoy peptide is a therapeutic peptide designed to disrupt the interaction between the RNA-binding protein Musashi1 (MSI1) and Argonaute2 (AGO2). In glioblastoma multiforme (GBM), MSI1 translocates to the cytoplasm under stress conditions and recruits AGO2 to form a complex that modulates mRNA stability, promoting tumor cell proliferation and survival. This decoy peptide mimics the C-terminal domain of MSI1, which is the site of direct binding to AGO2, thereby competitively inhibiting the formation of the MSI1/AGO2 complex. Preclinical studies in orthotopic mouse models of GBM have shown that delivery of this peptide effectively reduces stress-induced tumor progression, suggesting a novel peptide-based therapeutic strategy against refractory malignancies.

Other names
MSI1-C-terminus decoy peptidesMSI-1-C-terminus decoy peptidesMSI 1-C-terminus decoy peptides
02

Targets

AGO2 (Argonaute RISC catalytic component 2)

Beyond the preview

Go deeper on MSI1-C-terminus decoy peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSI1-C-terminus decoy peptide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call